Transcriptomic signatures of neuronal differentiation and their association with risk genes for autism spectrum and related neuropsychiatric disorders.

Permalink
https://escholarship.org/uc/item/7zz3f8gb

Journal
Translational psychiatry, 6(8)

ISSN
2158-3188

Authors
Chiocchetti, AG
Haslinger, D
Stein, JL
et al.

Publication Date
2016-08-02

DOI
10.1038/tp.2016.119

Peer reviewed
Transcriptomic signatures of neuronal differentiation and their association with risk genes for autism spectrum and related neuropsychiatric disorders

AG Chiocchetti1, D Haslinger1, JL Stein2, L de la Torre-Ubieta2, E Cocchi3, T Rothämel4, S Lindlar1, R Waltes1, S Fulda5, DH Geschwind2 and CM Freitag1

Genes for autism spectrum disorders (ASDs) are also implicated in fragile X syndrome (FXS), intellectual disabilities (ID) or schizophrenia (SCZ), and converge on neuronal function and differentiation. The SH-SYSY neuroblastoma cell line, the most widely used system to study neurodevelopment, is currently discussed for its applicability to model cortical development. We implemented an optimal neuronal differentiation protocol of this system and evaluated neurodevelopment at the transcriptomic level using the CoNTeXT framework, a machine-learning algorithm based on human post-mortem brain data estimating developmental stage and regional identity of transcriptomic signatures. Our improved model in contrast to currently used SH-SYSY models does capture early neurodevelopmental processes with high fidelity. We applied regression modelling, dynamic time warping analysis, parallel independent component analysis and weighted gene co-expression network analysis to identify activated gene sets and networks. Finally, we tested and compared these sets for enrichment of risk genes for neuropsychiatric disorders. We confirm a significant overlap of genes implicated in ASD with FXS, ID and SCZ. However, counterintuitive to this observation, we report that risk genes affect pathways specific for each disorder during early neurodevelopment. Genes implicated in ASD, ID, FXS and SCZ were enriched among the positive regulators, but only ID-implicated genes were also negative regulators of neuronal differentiation. ASD and ID genes were involved in dendritic branching modules, but only ASD risk genes were implicated in histone modification or axonal guidance. Only ID genes were over-represented among cell cycle modules. We conclude that the underlying signatures are disorder-specific and that the shared genetic architecture results in overlaps across disorders such as ID in ASD. Thus, adding developmental network context to genetic analyses will aid differentiating the pathophysiology of neuropsychiatric disorders.

Translational Psychiatry (2016) 6, e864; doi:10.1038/tp.2016.119; published online 2 August 2016

INTRODUCTION

Autism spectrum disorders (ASD) share some of their genetic architecture with other neuropsychiatric disorders such as fragile X syndrome (FXS), schizophrenia (SCZ) and intellectual disabilities (ID). It is known that the fragile X mental retardation protein (FMRP), a translational repressor causal for FXS, specifically binds ASD risk genes,1 and common variants of genes involved in the regulation of FMRP pathways are associated with ASD.2 In addition, several genes affected by copy number variations (CNVs) and mutations detected in ASD patients were also associated with SCZ3,4 or ID.5,6 However, integrative analyses investigating the functional overlap between ID and ASD showed that only ASD genes, but not ID-implicated genes, are enriched in neocortical developmental networks.7,8 Thus, it is unclear to which extent the genetic overlap reflects shared or differential pathomechanisms. Investigating the effect of disease risk genes on neurodevelopment is of major interest to understand the etiology and pathophysiology of these neuropsychiatric disorders. Feasible, reproducible and scalable cell models are thus needed to elucidate the functional consequences of genetic variants. Human neuronal models used so far include neurons differentiated from embryonic stem cells, induced pluripotent stem cells (iPSCs), human neuronal progenitor cells (NPCs) or neuroblastoma cell lines. The choice between the different cell models involves clear tradeoffs. The SH-SYSY neuroblastoma cell line is the most cited in vitro model in neuropsychiatric research and has the advantage of low cost, ease of culture (feasibility), reproducibility and available literature. Despite its origin from a tumour, its neuroectodermal lineage allows investigating neuronal phenotypes of neurodevelopmental and neurodegenerative diseases. New models based on embryonic stem cells or iPSCs promise to recapitulate in vivo development more faithfully than this or other cell lines,9 leading to the question of the most appropriate use of SH-SYSY models in modelling of neuropsychiatric disorders. Yet, it should be acknowledged that embryonic stem cell, iPSC and human NPC models are expensive, and culturing and differentiating of these cells in a reproducible manner is far more difficult.

1Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, JW Goethe University Frankfurt, Frankfurt am Main, Germany; 2Neurogenetics Program, Department of Neurology, Center for Autism Research and Treatment, Semel Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; 3Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy; 4Institute of Legal Medicine, Hannover Medical School, Hannover, Germany and 5Institute of Experimental Cancer Research in Pediatrics, Frankfurt am Main, Germany. Correspondence: Dr AG Chiocchetti, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, JW Goethe University Frankfurt, Goethe University Deutschordenstrasse 50, Frankfurt am Main 60528, Germany.
E-mail: andreas.chiocchetti@kgu.de
Received 28 September 2015; revised 27 April 2016; accepted 29 April 2016
than for SH-SY5Y cells. Recognising the limitations of all model systems, it is therefore important to understand how the optimal protocol for using the efficient SH-SY5Y model system recapitulates in vivo development, which will be helpful in guiding this and future studies. In summary, we focused on improving neuronal differentiation of SH-SY5Y cells because of feasibility, reproducibility, the broad use of this model in previous publications and the large data resources available.

Goldie et al. summarised that 72% of SH-SY5Y differentiation protocols used all-trans retinoic acid (RA) only, whereas others used a sequential treatment with RA and brain-derived neurotrophic factor (BDNF) or alternative agents such as 12-O-tetradecanoylphorbol-13-acetate. However, no study has used RA and BDNF in combination, as it is currently used in NPC and iPSC differentiation protocols. BDNF is strongly involved in differentiation and maintenance of cortical neurons. Here, we tested whether a continuous exposure of SH-SY5Y to RA and BDNF (cRA-BDNF) improves differentiation ability compared with RA only or subsequent RA-BDNF (sRA-BDNF) protocols. Therefore, we evaluated publicly available and newly generated transcriptomic signatures of these three methods (RA-only, sRA-BDNF, and cRA-BDNF, the data set produced here) for their capacity to model cortical development implementing the CoNTeXT framework specifically developed for this use. The CoNTeXT framework is based on a machine-learning algorithm trained on genome-wide transcriptomic data available through the Brain Span Atlas of the developing brain. This data set includes cross-sectional transcriptomic data across all human brain regions spanning the whole lifespan (2 weeks after conception to >60 years). The CoNTeXT framework predicts developmental stage and region of origin of a transcriptomic signature, analyses gene-network preservation based on weighted gene co-expression analysis and compares developmental transitions. The accuracy of predictions can be estimated based on empirical modelling using rank–rank hypergeometric overlap (RRHO) tests provided in the original publication by Stein et al.

To then exploit our improved cell system, we performed a biostatistical analysis of generated transcriptomic signatures. Finally, we delineated specific regulatory modules and signatures of neuronal differentiation and their association with neuropsychiatric disorders comparing ASD with FXS, ID and SCZ.

**MATERIALS AND METHODS**

**Neuronal differentiation of SH-SY5Y**

SH-SY5Y identity was confirmed by DNA fingerprinting using AmpFESTR Profiler and AmpFESTR NGM Select PCR Amplification Kits (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s protocol. Cells were proliferated under standard conditions (Dulbecco’s modified Eagle medium, 10% fetal bovine serum, 1% sodium pyruvate (all Life Technologies, Carlsbad, CA, USA) and 1% penicillin/streptomycin (PAA, Dortmund, MA, USA)). Here, we used a protocol for neuronal differentiation applying RA and BDNF simultaneously in contrast to currently used standard protocols. Cells were differentiated in Neurobasal-A medium with 1× GlutaMAX, 1× B-27 supplement (all Life Technologies), 10 μM RA, 2 μM cAMP (both Sigma-Aldrich, St. Louis, MO, USA), 50 ng ml⁻¹ hBDNF (ImmunoTools, Altenoythe, Germany), 1% PAA and 20 μM KCl over a time course of 11 days changing the medium every other day. The time points for mRNA analysis were set 24 h after changing the medium and were as follows: 0 (undifferentiated cells), 1, 3, 5, 7, 9 and 11 days in vitro (DIV).

**Validation of differentiation.** Markers for neuronal differentiation were analysed at mRNA and protein levels using real-time reverse transcriptase-PCR (RT-PCR) and western blot analyses, respectively. We used CDK1 as marker for cell division and MAPT as marker for axon outgrowth (Supplementary Methods and Supplementary Table 1).

**Whole-genome expression analysis**

**mRNA microarray raw-data SH-SY5Y.** For whole-transcriptome analysis of the SH-SY5Y cell line, whole RNA of three biological replicates of time points 0 DIV to 11 DIV was extracted using the GeneJet RNA Purification Kit according to the manufacturer’s protocol (Fermentas) including DNase treatment. All samples passed quality check analysis (RNA Integrity Number RIN>7.0, Bioanalyzer, Agilent, Santa Clara, CA, USA). Microarray analysis using HumanHT-12 v4 Expression BeadChips (Illumina, San Diego, CA, USA) was performed. Principal component analysis (PCA) was used to check for systematic variation on the microarray (Supplementary Table 2). Genes that were significantly (detection P-value < 0.05) expressed above background in all replicates were defined as the expressed neuronal transcriptome (N = 11 392).

Hierarchical cluster analysis of the top 2 000 genes by variance (distance = 1 – Pearson correlation, method = average linkage) was used to identify methodological outliers. No samples presented with high branch points in the cluster dendrogram. Principal component analysis (PCA) and dynamic time warp analysis (DTW) analyses confirmed similarity of the biological replicates (Supplementary Figure 3).

Microarray mRNA expression of selected ASD-risk genes and neuronal differentiation-specific markers were validated using relative real-time RT-PCR and compared using Pearson correlation analysis (Supplementary Methods, Supplementary Figure 1 and Supplementary Table 1).

**CoNTeXT analysis:** We used the recently developed framework of algorithms matching in vitro mRNA expression signatures to transcriptomic atlases of in vivo brain development. The CoNTeXT algorithm ([http://context.semel.ucla.edu/](http://context.semel.ucla.edu/)) is a machine-learning framework that determines the temporal and regional identity as well as preservation of co-regulated modules based on expression signatures from 18 different stages of the human lifespan representing early embryonic stage to an age greater than 60 years. Accuracy is dependent on the overlap in gene signatures between the in vitro and in vivo data. Given a ρ-log10(P-value) = 299 in the RRHO analysis, the accuracy of predictions was estimated to be >96%. The effect of time on CoNTeXT scores for each stage and region and for each data set were tested using linear regression models. Details on the algorithms and accuracy estimation are published elsewhere.

Data sets used for comparison of SH-SY5Y differentiation protocols: Raw data were downloaded from the gene expression omnibus GEO database ([http://www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo/)). The RA-only data set (Korecka data set) included transcription signatures of cells cultured for 8 days with and without all-trans RA only. GEO Acc Nr: GSE43368. The sRA-BDNF data set (Nishida data set) included the ECACC-derived SH-SY5Y cell line treated with RA and BDNF for 5 and 3 days subsequently. GEO Acc Nr: GSE9169. All data sets were log2-transformed and quantile-normalised as described above.

Identification of differentially expressed genes: In this analysis only the expressed gene set (N = 11 392) was used. We applied linear fixed-effect models (nlme package in R) accounting for random effects between the three replicates with the two dichotomized time points (for example, 0 DIV vs 3 DIV) predicting expression values. Only differentially expressed (DEX) genes with (Benjamini–Hochberg) false discovery rate (FDR) < 0.05 (adjustment for N = 11 392 tests) were included in GO term analysis.

Dynamic time warp analysis: Westler et al. have successfully adapted Dynamic time warp (DTW) analysis to identify time-dependent gene activation. The authors provided evidence that the DTW distance increases linearly with background noise. DTW analysis was performed using the ’dtw’ package in R. All expressed genes were analysed (N = 11 392) and compared with a noise matrix (Supplementary Methods). We defined the maximum DTW distance (DTW dissimilarity score) as the intercept of a
linear model predicting the DTW distance in dependence of background noise for each gene in our cell line model (Supplementary Figure 4).

Genes with a DTW distance larger than \(2 \times \) noise intercept (upper 95% boundary) were considered for further analysis. Genes with similar regulatory patterns were grouped by k-means cluster analysis on the Euclidean distances. Optimal number of clusters was defined applying the ‘elbow criterion’ based on the Scree-plot of within-cluster sum of squares around cluster means (Supplementary Figure 4) as suggested.21

Parallel independent component analysis: Parallel independent component analysis (pICA) analysis is an exploratory approach based on blind source separation techniques to identify regulatory genes contributing to biological processes.20,21 Here, we used the ‘fastICA’ package in R-program and iterated the pICA 250 times extracting two to eight components, respectively (Supplementary Methods). A total of four components was extracted with a mean correlation coefficient r > 0.999 of all gene loads (first principle component) over all iterations. Genes were considered as significant if their load within the components was above the conservative cutoff of score > 3 (gene load; Supplementary Figure 5). The analysis was performed using the whole neuronal transcriptome (N = 11 392).

Weighted gene co-expression network analysis: Weighted gene co-expression network analysis (WGCNA) analyzes co-expression patterns between genes and identifies gene sets (modules) based on their topological overlap (Supplementary Methods). WGCNA was performed using the ‘WGCNA’ package in R as recommended.21 Here, to identify network modules of regulatory genes only, we used the neuronal transcriptome gene set (N = 11 392) and calculated a topological overlap matrix based on a signed adjacency (Supplementary Methods and Supplementary Figure 6).

Network analysis and hub gene identification: Genes with a high functional impact within a network are hypothesized to be highly connected and members of several regulatory pathways (that is, hub genes). The connectivity of a gene is defined by the sum of its weighted correlation with the other genes as defined through the adjacency measure in the WGCNA. We also defined network centrality (Degree) of a node (number of connections a gene has) and betweenness centrality (the number of shortest connections across all nodes passing through the node of interest). To reduce hyperconnectivity, we only considered two genes to be connected (Degree) if their expression correlated with a Spearman cor > 0.90. All calculations were performed using the ‘igraph’ package.

GO-term enrichment analysis: GO-term enrichment was performed with the topGO package using the weightGO algorithm, where the significance of a GO-term is weighted by the efficiency in detecting relevant associated terms. Individual tests are not independent, and therefore multiple testing does not apply. P-values extracted thus can be considered as corrected for multiple testing. The gene universe was defined as the 11 392 genes significantly expressed.

Risk gene enrichment analysis: In total, we tested the following 14 gene lists: gene counts refer to genes targeted on our chip: ‘01_AutismKB’; genes (N = 3 050), non-syndromic and/or syndrome, listed in AutismKB; ‘02_AutismKB_core’: genes (N = 170) included in the high reliability core data set of the AutismKB database (for details on these two lists see http://autismkb.cbi.pku.edu.cn); ‘03_SFARI_all’; all 3 411 genes listed in the SFARI Gene Autism Database,25 excluding non-supported genes. ‘04_SFARI_scores’; all 250 genes listed in the SFARI Gene Autism Database with a score ≥ 4, that is, genes with minimal evidence in at least one candidate gene study. ‘05_Veinougrey_M12’; N = 443 genes within a network module (M12) identified to be differentially regulated in post-mortem brains of ASD individuals.26 ‘06_Veinougrey_M16’; genes (N = 386) also reported by Veinougrey et al.27 ‘07_Gilman Netbag’: ASD-risk genes (N = 72) identified through network-based analysis of ASD associated rare de novo CNVs.28 ‘08_losssofRDNY’: genes (N = 672) targeted by rare de novo likely gene-disrupting variants identified through exome sequencing.29 ‘09_DeRu- beis_RCV’: genes (N = 100) recurrently targeted by rare coding variants.30 ‘10_Darneill_FMRP’: genes (N = 837) whose mRNAs are directly bound by the FMRP gene. ‘11_Parikhak_ID genes’: genes (N = 388) implicated in ID retrieved from multiple publications.31 ‘12_Pinto_ID genes’: manually curated list of genes (N = 252) implicated in monogenic ID.13 ‘13_Fro- mer_SCC_allRDNY’: genes (N = 676) targeted by rare de novo variation in SCZ.31 ‘14_Cocchi_Pruning’: a manually curated list of (N = 117) genes involved in pruning.32 For detailed information on all gene lists see Supplementary Table 3 and Supplementary Figure 7.

Enrichment testing was performed applying Fisher’s exact test. Benjamini-Hochberg correction for multiple testing (number of risk-gene lists times number of clusters identified in each analysis) was applied. As the reference genome, the list of all 20 318 Entrez Genes targeted on the chip was used.

RESULTS

Basic confirmation of neuronal differentiation

SH-SY5Y cells continuously exposed to RA and BDNF (cRA-BDNF) for 14 days yielded a stereotypical multipolar neuronal morphology with one to two long axon-like processes and several shorter dendrite-like processes as reported in the original publication by Cinicas et al.19 Robust differentiation was confirmed by known markers for cell cycle (CDK1) and axonal outgrowth (MAPT), which were down-regulated and up-regulated, respectively (Supplementary Figure 1a). Microarray expression data of ASD risk genes (SHANK3, NRXN1, CNTPNAP2, DHCRT7, GABRB3 and GRIK2), glutamatergic receptors (GRIN1, GRIA2, GRM1 and GRM4) and dopaminergic markers (TH and DRR4) that were previously reported to be regulated during neuronal differentiation,33 showed high correlation with expression levels assessed by real-time RT-PCR demonstrating technical reproducibility of microarray data (correlation coefficients ranging from 0.561 (GRIA2) to 0.984 (NRXN1); Supplementary Figure 1b). Markers for neuronal subtypes, including cholinergic, dopaminergic, serotonergic, GABAergic and glutamatergic neurons were expressed (Supplementary Figure 2). The dopamine transporter (DAT1) was strongest expressed at undifferentiated stages and down-regulated during differentiation. The dopaminergic marker TH (Supplementary Figure 2) was not regulated, whereas cholinergic markers (ACHE, SLC18A3) were up-regulated. We also observed a modest up-regulation of glutamatergic (SLC17A7) and GABAergic (SLC32A1) transporters. Markers specific for motor neurons were expressed but not regulated during differentiation. The implemented differentiation protocol thus yielded an unspecific mixture of neurons.

Evaluation and comparison of the improved neuronal differentiation method

Similar to findings in the human brain,34 the SH-SY5Y neuronal transcriptome, that is, the genes expressed above microarray background in our cell model included 11 392 out of 20 318 genes targeted on the microarray.

The CoNTeXT framework35 was used to estimate differentiation stage and brain-regional identity of our cell model. Expression signature of cRA+BDNF SH-SY5Y cells was reminiscent of brain tissue developed for at least 15–19 weeks post conception (Stages 5–8; accuracy > 96%) and was most likely to be of a cortical identity (accuracy > 90%; Figure 1a). In contrast, the two published data sets on SH-SY5Y neurodevelopment that differentiated cells either by RA treatment-only (RA-only)7 or by sRA+BDNF16 did not show a transcriptional phenotype as mature as cells differentiated by the continuous exposure to RA and BDNF as used here. Regression analysis of CoNTeXT scores confirmed this observation: changes in our data set for stages 1, 2, 4–10, 12 and 15 were significantly depending on time (Supplementary Table 4), whereas no significant association between differentiation over time and CoNTeXT scores was identified for the Korecka data set. Only scores for Stage 1 of sRA+BDNF-treated SH-SY5Y were significantly altering over time. In summary, RA-only cells were least mature, followed by sRA+BDNF cells.

cRA+BDNF and sRA+BDNF cells matched cortical regions with no significant changes over time, whereas RA-only were striatal at the beginning of differentiation and turned more cortical at later stages. However, changes were not significant. Co-regulatory network modules (Figure 1b) were specifically preserved in the
sRA-BDNF and cRA+BDNF, but not the RA-only-treated cells. This included preservation of mitosis, neuronal development, glutamatergic and GABAergic transmission, but not modules related to synaptogenesis, glia-genesis or immune response (for details see Supplementary Table 4 and previous publications by Stein et al.).

In the RRHO maps (Figure 1c), only our improved model showed similarities with the transition from early stages 1 or 2 to stage 5 and beyond, including both down and up-regulated gene sets. Mapping of transcriptional signatures of mid-fetal cortical layers from gestational stage 5–6 (ref. 18) revealed that sRA-BDNF and cRA+BDNF treatments can model the transition of cells from the ventricular layers to the subplate layer, where the cRA+BDNF system showed highest significance and accuracy of prediction (96% for stage and above 85% for regional identity; for details see Materials and Methods section and original CoNTeXT publication).

Identification of genes implicated in neuronal differentiation
To robustly identify the subset of genes regulated during neural development, we implemented three complementary statistical approaches: DEX analysis identifies genes by comparing two time...
Figure 1. Evaluation of neuronal differentiation comparing three SH-SY5Y protocols. (a) CoNTExt analysis comparing mRNA signatures previously published (Korecka; Nishida) and generated here (Chiocchetti). mRNA signature of the cells (Chiocchetti data set) differentiated by continuous exposure to retinoic acid (RA) and brain-derived neurotrophic factor (BDNF) was showing a more mature phenotype than the other two sets. Our data set was more similar to the cortical area and was consistent of 15–19 weeks post conception (Stage 5) or above. In addition, our data set showed no remissence for earlier stages after 11 days in vitro (DIV; see black arrows). Regression analyses testing association of time with CoNTExt scores are provided in Supplementary Table 4. (b) Module preservation analysis comparing co-expression network modules in vitro vs in vitro. Z-scores are plotted against the number of genes within each module. Highest significant preservation (Z-score) is observed for cell cycle-related (red, magenta) modules in both data sets using BDNF (Nishida and Chiocchetti). In our set-up, neuronal function modules such as ‘glutamatergic synaptic transmission, axon and dendrite development’ (salmon, green) or ‘GABAergic synaptic transmission and synaptic vesicle exocytosis’ (lightgreen) were nominally significant, whereas ‘axon guidance, neuronal migration and GTPase activity’ (purple) showed intermediate (Z-score 2–10) preservation. No preservation was observed for modules related to synaptic transmission (pale-turquoise, yellow), gliogenesis (tan, yellow) or immune response (black, orange) in any data set. Dashed lines mark Z-scores blue = 1.96, red = 1.4, green = 10. For details see Supplementary Table 4. (c) Mapping of transitions between stages and cortical layers is shown as rank–rank hypergeometric overlap (RRHO) maps. Genes were ranked based on signed P-values comparing undifferentiated versus differentiated cells. These ranks were binned (200 genes each) and respective genes were tested using a hypergeometric test for overlap with the genes in all bins generated of in vivo comparison of stages (x vs y axis) or cortical layers, respectively. P-values of each comparison are plotted. The coloring of −log10 (P-values) is scaled to the maximum values observed in the original publication by Stein et al.3 The maximum P-value within each analysis is shown as a measure for overall accuracy. Simulations performed by Stein et al.3 predict that given a −log10(P-value) ~ 300 in the stage transition mapping the CoNTExt algorithm can predict the developmental stage with an estimated accuracy ~96% and brain region accuracy ~90%. For details see original publication.3 AMY, amygdala; CBC, cerebellar cortex; HIP, hippocampus; STR, striatum; THAL, thalamus.

points, DTW analysis identifies genes that are regulated across a temporal trajectory and ICA extracts individual processes and underlying genes. Similar to a recent publication, a total of N = 6 049 genes were DEX with a FDR < 0.05 at least at one time point compared with undifferentiated cells (Figure 2a and Supplementary Table 5). N = 3 169 genes were up-regulated and N = 2 894 genes were down-regulated, of which 14 genes were up-regulated at one time point and down-regulated at another (ALDH9A1, BCL11A, CNPD2, CTSF, EPBH4, GREM2, KCNG1, MRAP2, NETI, PHKB, SCAND1, TEAD2, TRAM2 and ZNF217). No gene was significantly (FDR < 0.05) regulated after 1 day of differentiation. However, a total of 3 387 genes were regulated with nominal significance at that time point. Most of the transcriptional regulation occurred during the first week. In accordance, we observed higher similarities between later time points than earlier time points (Supplementary Figure 3). GO-term analysis attributed up-regulated DEX genes to synaptic exocytosis and transmission and extracellular matrix re-organization, whereas genes down-regulated belonged to GO-terms mitosis or DNA replication (all weighted P-values < 10e−4; Figure 2b and Supplementary Table 5). A similar pattern was observed when analyzing regulated genes of each time point individually, linearly with the expected induction of neuronal differentiation and the cessation of cell division.

The DTW approach identified 509 genes with continuous or dynamic changes over time (Figure 2c, Supplementary Table 6 and Supplementary Figure 4). All but four of these genes were a subset of the DEX gene set. Consequently, 8.3% of the total DEX genes were also dynamically regulated during neuronal differentiation.

The DEX genes clustered into five trajectories or stimulatory responses (Figure 2c); three showed a positive response (coral, lavender and skyblue clusters) and two a negative response (yellow and aquamarine clusters). The cluster with the strongest positive regulation (skyblue) comprised 18 genes significantly enriched for RA response (Figure 2c and Supplementary Table 6). The coral (low-positive responder) and lavender (intermediate-positive responder) were enriched for genes related to developmental processes (GO-terms extracellular matrix disassembly and developmental growth) and neuronal signaling, respectively. The down-regulated clusters were associated with cell division and cell cycle (yellow) or autonomic nervous system development and ventricular septum development (aquamarine). The yellow cell cycle cluster showed an initial weak positive response after induction of differentiation before changing to the inhibitory response.

Finally, four components were observed by ICA (Figure 3a) with a total of N = 699 high loading genes (Supplementary Table 7 and Supplementary Figure 5). On the basis of GO-term enrichment analysis (Figure 3b and Supplementary Table 7), the four biological entities (C1–4) were labeled as differentiation and cellular organization (C1), developmental processes (C2), cell cycle regulation (C3) and protein synthesis and modification processes (C4). In addition, C1 contained several zinc-finger proteins and DNA-binding proteins supporting the idea that C1 is a transcriptional regulatory process.

Combining all genes identified through DEX, DTW and ICA analyses yielded 6 262 genes implicated in neuronal differentiation. Of these, 299 were identified in all three analyses (Figure 4a). This high-confidence gene set was implicated in cell cycle regulation.

Co-expression network analysis
WG CNA identified 20 regulatory modules (Figures 4b–d and Supplementary Table 8). As expected, modules up-regulated during early neuronal differentiation were enriched for processes needed for membrane remodeling (magenta), protein stabilization (lightcyan) or axonal guidance (pink). Late activated modules were associated with synaptic transmission (blue) or dendrite development (darkgreen). Modules up-regulated during early phases of differentiation only were related to inflammatory response (light-yellow) and cellular fatty-acid metabolism (darkgrey).

In contrast, early down-regulated modules were attributed to cell division (black) or mitochondrial organization (greybrown). Modules inhibited at later stages also included genes associated with cell cycle regulation (turquoise) and DNA metabolic processes (cyan, purple). Modules associated with splicing (darkturquoise) or cell projection and transcriptional regulation were undulating over time.

Enrichment of risk genes in regulatory gene modules of neuronal differentiation
We next tested identified modules and gene sets for enrichment with genes implicated in either ASD, FXS, SZ or ID using 14 published lists of disorder-specific risk genes (Supplementary Table 5). We first tested the up- and down-regulated DEX gene sets and observed a significant (FDR < 0.05) enrichment among the combination of all genes up-regulated at any time point for risk genes of all four disorders (Figures 5a and b and Supplementary Table 9). The strongest enrichment (log odds ratio (OR) = 1.20, FDR < 0.01) was observed for genes belonging to a
network module (M12) that has previously been identified to be DEX in ASD brains. Among the set of down-regulated genes, only genes implicated in ID, but not in any of the other neuropsychiatric disorders, were significantly enriched. When studying the individual time points, enrichment for ASD risk genes listed in the Autism knowledgebase (AutismKB) was similar over all time points. However, genes up-regulated at later time points (7–11 DIV) were more likely (log OR > 0.81, all FDR < 0.01) to be FMRP targets than those at earlier time points (2 DIV: log OR = 0.32, FDR > 0.1; 5 DIV: log OR = 0.61, FDR < 0.01). In addition, we observed significant under-representation (log OR < −0.73, FDR < 0.01) after 5 and 9 DIV of these targets among down-regulated genes (Figures 5a and b). Genes regulated after 5, 7 and 11 DIV were enriched for ID-implicated genes only. In addition, enrichment for the ASD-associated module M12, which is a synapse and neuron function-related gene cluster,
increased over time, whereas enrichment for the glia and ASD-associated module M16 decreased. SCZ-implicated genes targeted by de novo mutations showed a weak association (FDR < 0.1) with up-regulated genes after 7 DIV. Genes implicated in synaptic pruning were, similar to ASD genes, enriched among up-regulated genes only.

Next, we investigated whether the risk genes implicated in the neuropsychiatric disorders of interest were enriched in dynamically regulated genes (DTW genes; Figure 5c). We report an association with ASD-risk genes, specifically when testing all DTW genes (log OR = 0.57, FDR < 0.01). FMRP-targeted genes were enriched among the set of genes associated with extracellular matrix assembly and developmental growth. ASD genes listed in the AutismKB database were enriched among the aquamarine (nervous system development), the lavender (synaptic transmission) and the coral (development) clusters. No significant enrichment was identified for SCZ- or ID-implicated genes.

When testing the specific underlying biological processes (that is, independent components; ICA), only genes listed in AutismKB and the glia-associated ASD-module M16 were found to be enriched among genes contributing to developmental processes (ICA c2) or translational processes (ICA c4; Figures 5d).

ASD genes were predominately enriched among up-regulated modules identified through WGCNA, that is, the blue, darkgreen, lightcyan, orange and pink modules (Figure 5e). These modules refer to synaptic transmission, dendrite development, tissue remodeling, histone modifications and axon guidance, respectively. The blue and pink modules were also associated with FMRP targets. One down-regulated module (purple, transcriptional response to stress) and one up-regulated gene set (royalblue, branching, cell adhesion and morphological development) were associated with genes identified in mutation screens of ASD and SCZ as well as FMRP targets (all log OR > 0.97, FDR < 0.05), but not with ID-implicated genes. Despite the overlap of risk genes between ASD and ID, only the darkgreen module was associated with ID and ASD. Again, for ID genes we observed that the down-regulated darkturquoise gene set is significantly enriched for ID genes but not for FMRP targets.

Finally, we constructed a correlation network of the neuronal transcriptome to test the hypothesis that genes implicated in neuropsychiatric disorders are likely to be among the top connected hub genes, defined as the upper 10% using network measures for Connectivity, Betweenness and Degree (for details see Materials and Methods). Here, we showed that ASD and ID genes are enriched among two different types of hub genes: ID genes can be found among highly connected genes (Degree, Connectivity; log OR = 0.79, FDR < 0.05), whereas ASD risk genes were among hubs with high influence on information transfer within a system (Betweenness, log OR = 0.40, FDR < 0.01), that is, genes that potentially connect networks or modules (Figure 5f and Supplementary Table 9).

Voineagu’s Module M16 genes (log OR = 1.06, FDR < 0.01) and pruning genes (log OR = 1.21, FDR < 0.01) were also enriched among highly connected genes, whereas genes belonging to gene set M12 were likely to be among information transfer genes (Betweenness, log OR = 1.06, FDR < 0.01).
Figure 4. Overlap of results and weighted gene co-expression network analysis. (a) Overlap of gene sets identified through linear regression (false discovery rate (FDR) < 0.05; Figure 2a) DEX, dynamic time warping analysis (DTW; Figure 2c) and parallel independent component analysis (pICA; Figure 3). (b) Weighted gene co-expression network analysis (WGCNA) module definition based on topological overlap; colors correspond to modules identified. (c) Module Eigenvalues (that is, first principal component; Eigengene) of log2 fold changes of the respective modules normalised to time point 0 DIV. (d) GO-term enrichment analysis of identified network modules. Weighted P-values of the five most significant terms are shown. Green line marks the weighted P < 0.05 cutoff.
DISCUSSION

Continuous exposure to RA and BDNF of SH-SY5Y cell line improves neuronal differentiation

As the utility of the SH-SY5Y model to study neuronal differentiation depends at least partially on how well it models in vivo development, we tried to improve current differentiation protocols and evaluated the capacity of these differentiated cells to model cortical development. One major limitation of this model is its origin from a tumor. The cell line shows several well-described cytogenetic aberrations including oncogene-spanning CNVs. Tumor-derived cell lines have a highly active, dysregulated cell cycle, which might bias the interpretability of cell cycle-associated findings. However, to our knowledge, the reported CNVs do not span major genes associated with neuronal differentiation and neuropsychiatric disorders under study here.

The result of the ConTEXT algorithm shows that SH-SY5Y cell lines were differentiated toward developmental stages 5–8, which is beyond the stages achieved using established protocols. In addition, we observed preservation of modules highly relevant for ASD, that is, glutamatergic and GABAergic pathways. However, neither the improved cell model nor cells derived from the original protocols show preservation of modules associated with synaptic transmission. In line with current discussions about neuronal differentiation methods, we propose that protocols applied to neuronal in vitro models need to be evaluated in more detail.

Most differentiation protocols for SH-SY5Y cells including either RA-only or sequential treatment with RA and BDNF report a dopaminergic phenotype. However, the continuous RA-BDNF exposure protocol used here does not result in up-regulation of the rate-limiting enzyme of dopamine, that is, the TH, and leads to a down-regulation of the dopamine transporter DAT1. A negative correlation between BDNF levels and dopamine receptors DRD2 and DRD3 expression has previously been reported in rat models for stress linking the two systems. We hypothesize that the immediate activation of the BDNF/TrkB system during differentiation underlies the negative effect on the dopamine system. It is also interesting to note that the expression of tyrosine receptor kinase beta in SH-SY5Y cells is activated by RA and reaches its peaks after 5 days of exposure. Thus, in line with previous publications, we emphasize the importance of selecting differentiation agents and the temporal exposure of cells to these agents based on the specific research question related to the cell model.

In summary, it is true that SH-SY5Y cells may not allow investigating all functional aspects of neurons; the continuous exposure of SH-SY5Y cells to RA and BDNF improved differentiation and thus allows investigating genes relevant in early cortical differentiation.

Figure 5. Risk gene enrichment analysis. Disorder-implicated risk-gene lists were tested for enrichment in (a) up-regulated differentially expressed genes (DEX), (b) down-regulated DEX genes (no gene survived correction for multiple testing comparing time point 1 DIV; thus, enrichment testing was not applicable), (c) genes dynamically regulated (dynamic time warp (DTW)), (d) genes contributing to biological regulatory components (ICA); (e) modules identified by the weighted gene co-expression network analysis (WGCNA) and (f) the top 10% of expressed genes (DEX), (g) modules identified by the weighted gene co-expression network analysis (WGCNA) and (h) the top 10% of expressed genes (DEX).
Neuropsychiatric risk genes during neuronal differentiation
AG Chiocchetti et al

development and exploring regulatory networks associated with psychiatric disorders.

DEX, ICA and DTW analyses are complementary approaches to identify differentiation-related gene sets
Following our aim to fully characterize the neurodevelopment of our cell model, we applied DEX, DTW and ICA. Most of the genes identified through DTW were overlapping with DEX genes, identifying the subset of DEX genes that is regulated dynamically. In all, 70% of all genes identified through ICA were also identified in the DEX approach. This again shows the usefulness of implementing three complementary approaches to identify the whole set of genes that is implicated in neuronal development. Considering the GO-term enrichment analysis, we assume that the DTW-ICA-derived expression signature corresponds to modulatory mechanisms regulating growing structures, whereas the short-term (DEX only) regulatory pattern may imply cellular checkpoint mechanisms (for example, during cell cycle regulation).

Regulatory mechanisms of neurodevelopment are relevant in neuropsychiatric disorders
As expected, when analyzing DEX genes, cell cycle regulators were among the down-regulated, and neuron-related or differentiation-activating genes among the up-regulated set. When testing for risk gene enrichment we need to consider the overlap of gene lists across disorders. Specifically, genes implicated in ASD and FXS showed a strong overlap. This fact may in part explain the overlapping pattern of enrichment for these gene lists. However, despite the overlap between SCZ and ASD risk genes or between SCZ and SCZ-associated synaptic pruning genes, the enrichment signature was different between the lists. Additional complexity is added by the differing lengths of the disorder-specific gene lists, which results in differential power to detect a significant enrichment. Finally, it is to be expected that module-specific gene enrichment observed for a short list is even more easily observed for a long gene list. This, however, is not the case. Therefore, we are confident that our conclusions with respect to disorder-specific risk gene enrichments are valid.

In our hypothesis-free approach, we confirmed the association of ASD-, FXS-, ID- or SCZ-implicated genes with regulation of neuronal differentiation. In contrast to the other disorders, only the ID-implicated genes were enriched among down-regulated sets, pointing to a major difference in the underlying pathomechanisms despite the genetic overlap.

Our findings confirm a previous prediction of a computational study reporting that variants associated with ASD specifically will disrupt genes that are positive regulators of biological processes. This can now further be complemented by the finding that this does not apply to variants causing ID, as these also affect negative regulators. It has to be considered here that rare de novo CNVs detected in ASD patients are enriched for ID-implicated genes. Thus, to understand whether disruption of negative regulators of neurodevelopment induces a specific subtype of ID even in ASD individuals, we propose testing whether loss of function mutations or gene-dosage reductions of negative or positive regulators are specific to subgroups of patients with ID or with ASD and ID.

The specific analysis of dynamically regulated gene sets further suggests that ASD- and FXS-implicated genes, but not ID and SCZ-risk genes, are indeed expressed during the full trajectory of early neuronal differentiation. The overlapping genetic enrichment of ASD- and FMRP-targeted genes in the extracellular matrix-related cluster may be driven by the overlap between the gene lists. Interestingly, in this cluster we also observed enrichment for genes of functional networks targeted by rare de novo CNVs in ASD and genes belonging to the synaptic M12 ASD-associated module identified in a post-mortem study.

ASD genes themselves are likely to be associated with developmental processes as confirmed in the ICA analysis here. This refines our hypothesis towards an association of ASD with promoters of developmental processes, and in addition suggests that dynamic regulators of neuronal development are more vulnerable to genetic variation specifically in ASD.

Network analysis of the neuronal transcriptome identified 20 modules. Again, we observed specific gene-set enrichment for ASD-, FXS-, ID- and SCZ-related genes. As detailed above, we exclude potential power issues because we did not observe enrichment of especially longer lists (that is, ASD_AutismKB). In addition, despite a significant overlap of the gene lists, enrichment itself was not overlapping and thus the enrichments were disorder- and module-specific. An example is the down-regulated turquoise cell cycle-related module, which was enriched for genes implicated in ID, but not for ASD-risk genes. Among these genes are, for example, the X-linked mental retardation gene UPF3B or the CHARGE syndrome-associated gene CHD7 (chromodomain helicase DNA-binding protein 7). Similar to the observations of DEX genes, the FMRP-targeted genes were underrepresented in this ID-gene-enriched cluster.

ASD genes, but not ID-implicated genes, were significantly enriched in the pink module, which can be labeled as protein trafficking and signaling response. Both processes have previously been associated with ASD. Besides the ASD-associated trafficking-related gene Neurobeachin (NBEA), this module contains also other several strong ASD-associated genes, that is, Neurilogen 3 (NGL3) or Neurexin 1 (NXN1).

Protein trafficking has already been shown to be affected by mutations in known ASD-risk genes, for example, Neurilogen 4 (NGLN4) mutations were reported to alter the transport of NGLN4 protein to the synaptic density. These findings add to the hypothesis that axonal pathfinding and protein transport might be pathomechanisms specific to ASD.

A specific overlap between ASD and ID was observed for a module associated with dendritic development (darkgreen), supporting the assumption that the pathological overlap between ASD- and ASD-related disorders with ID might originate from dendritic dysgenesis. Among the most prominent genes in this module is Reelin (RELN). RELN has repeatedly been associated with ASD as well as with lissencephaly and mental retardation. Another interesting candidate gene is the mitogen-activated protein kinase 3 (MAPK3/ERK3). This effector kinase mediates glutamatergic signaling in excitatory synapses, a process highly discussed in ASD etiological research.

Our results support the assumption that an overlapping pathomechanism between SCZ and ASD could be affecting transcriptional responses to stress and cell morphological processes. One of the most discussed transcriptional regulators in ASD, chromodomain helicase 8 (CDH8), is part of the royalblue, cell morphological module. Indeed, risk variants for CHD8 have been described for both ASD and SCZ.

ASD-risk genes are modulatory hubs during neuronal differentiation
To understand the broader functional impact of gene disruptions at a system's level, the network position of the respective genes needs to be considered. We have previously shown that a rare ASD variant can alter regulatory networks of oxidative stress, energy metabolism and translation. Here, we show that risk genes for ASD are likely to be modulatory hubs central in information transfer during neuronal differentiation and thus confirm that hubs are more likely to be affected by genetic risk variants for ASD. Interestingly, ASD genes, but not ID-implicated genes, were likely to be within the shortest paths between genes (information transfer hubs), whereas ID genes but not ASD genes were among the highly connected genes. This general
observation is in line with the genetic model strongly discussed in ASD research,59,60 where variants causing monogenic disorders show a high penetrance (that is, potentially affect central regulators) and variants involved in complex disorders show low penetrance (that is, modular variants).61 We thus suggest that rare highly penetrant variants affect genes of high connectivity disrupting larger parts of the network leading to a more severe phenotype such as ID, whereas variants affecting informational regulators can be bypassed and thus are of low penetrance such as in ASD without ID. This supports a recent publication reporting that common variants explain more of the ASD risk than rare variants.62 We hypothesize that a mutation can cause ID in ASD depending on the network position of the gene within a regulatory network. Interestingly, the observed enrichment for gene-disrupting mutations in ASD cohorts was driven by low IQ individuals.29 Thus, in complex disorders, the network position of an affected gene is a central parameter when estimating the pathological effect of a variant.

CONCLUSION

Our work takes an unbiased view on an optimized SH-SY5Y neuronal differentiation model. Although these cell lines do not model neurodevelopment as well as organoids, iPSC or primary progenitor cultures,63,64 transcriptome analysis indicates that when optimized they do capture early cortical development with high fidelity. Further, they have the advantages of ease and low cost; therefore, in some circumstances, especially molecular and drug screening, they provide a valuable model system. The profound translational analysis of the developmental trajectory showed that the genetic networks differ across related disorders and thus encourages future genetic studies that integrate genetic network structures to stratify neuropsychiatric patients for personalised interventions.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

We thank NN Parikshak for fruitful discussions and H Jelen for technical support. This work was supported by the Foundation of the JW Goethe University (to AGC and DH), the August Scheidel Foundation (to DH), the Held and Hecker estates 2013 (to AGC), the DAAD (German Academic Exchange Service) postdoc program 570704 83 (to AGC) and the National Institute of Mental Health (K09MH102357 to JS).

AUTHOR CONTRIBUTIONS

AGC designed the study, analysed data and wrote the paper; AGC, DH and SL performed experiments; AGC and DH performed computational analysis; DH strongly supported manuscript preparation; JLS and LiDiT-U supported ConText and RRHO analyses as well as manuscript preparation; EC supported manuscript preparation and provided pruning-gene lists; SF supported cell culture experiments; RW supported experimental work and manuscript preparation; DHG and CMF contributed to study design, supported the project and critically revised the manuscript.

REFERENCES

1 Darnell JC, van Driessche SJ, Zhang C, Hung KYS, Mele A, Fraser CE et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011; 146: 247–261.
2 Waltes R, Duketis E, Knapp M, Anney, Richard J L, Huguet G, Schlüter S et al. Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders. Hum Genet 2014; 133: 781–792.
3 Crespi BJ, Crofts HJ. Association testing of copy number variants in schizophrenia and autism spectrum disorders. J Neurodev Disord 2012; 4: 15.
4 Freitag CM, Agegpolous K, Huy E, Roethemundt M, Krakowiakz P, Meyer J et al. Adenosine A12A receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder. Eur Child Adolesc Psychiatry 2010; 19: 67–74.
5 Pinto D, Delabry E, Merico D, Barbosa M, Merikangas A, Klier L et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am J Hum Genet 2014; 94: 677–694.
6 Pinto D, Pagamenta AT, Klei L, Anney R, Merico D, Regan R et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010; 466: 368–372.
7 Parikshak NN, Luo R, Zhang A, Won H, Lowe JK, Chandran V et al. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell 2013; 155: 1008–1021.
8 Willsey AJ, Sanders SJ, Li M, Dong S, Tebbkenbamp AT, Muhle RA et al. Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell 2013; 155: 997–1007.
9 Stein JL, de la Torre-Ubieta, Luis, Tian Y, Parikshak NN, Hernández IA, Marchetto MC et al. A quantitative framework to evaluate modeling of cortical development by neural stem cells. Neuron 2014; 83: 69–86.
10 Koizhich OA, Hamilton R, Mallon BS. Standardized generation and differentiation of neural precursor cells from human pluripotent stem cells. Stem Cell Rev 2013; 9: 531–536.
11 Fernandes TG, Duarte ST, Ghazvini M, Gaspar C, Santos DC, Porteira AR et al. Neural commitment of human pluripotent stem cells under defined conditions recapitulates neural development and generates patient-specific neural cells. BioTechnol J 2015; 10: 1578–1588.
12 Goldie BJ, Barnett MM, Cairns MJ. BDNF and the maturation of posttranscriptional regulatory networks in human SH-SY5Y neuroblast differentiation. Front Cell Neurosci 2014; 8: 325.
13 Numakawa T, Suzuki S, Kumatamaru E, Adachi N, Richards M, Kunugi H. BDNF function and intracellular signaling in neurons. HistoI Histopathol 2010; 25: 237–258.
14 Leschik J, Eckenstaler R, Nieweg K, Lichteenecker P, Brigadski T, Gottmann K et al. Embryonic stem cells stably expressing BDNF-GFP exhibit a BDNF-release-dependent enhancement of neuronal differentiation. J Cell Sci 2013; 126: 5062–5073.
15 Korecka JA, van Kesteren Ronald E, Blaas E, Spitzer SO, Kamstra JH, Smit AB et al. Phenotypic Characterization of retinoic acid differentiated SH-SY5Y cells by transciptional profiling. PLoS ONE 2013; 8: e53862.
16 Nishida Y, Adati N, Ozawa R, Maeda A, Sakaki Y, Takeda T. Identification and classification of genes regulated by phosphatidylinositol 3-kinase- and TRKb-mediated signalling pathways during neuronal differentiation in two subtypes of the human neuroblastoma cell line SH-SY5Y. BMC Res Notes 2008; 1: 95.
17 Kang HJ, Kawasawa YL, Cheng F, Zhu Y, Xu L, Mi et al. Spatio-temporal transcription of the human brain. Nature 2011; 478: 483–489.
18 Miller JA, Ding S, Sunkin SM, Smith RA NG, L, Szafer A et al. Transcriptual landscape of the prenatal human brain. Nature 2014; 508: 199–208.
19 Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Ceña V et al. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem 2000; 75: 991–1003.
20 Wesler EM, Rosen E, Lu D, Osborn GE, Martin E, Rayboud H et al. Genome-wide analysis of a Wnt1-regulated transcriptional network implicates neurodegenerative pathways. Sci Signal 2011; 4: r65.
21 Tishbirani R, Walther G, Hastie T. Estimating the number of clusters in a data set via the gap statistic. J R Stat Soc B 2001; 63: 411–423.
22 Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M et al. International union of pharmacy. LK. Retinoic acid receptors. Pharmacol Rev 2006; 58: 712–725.
23 Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008; 9: 559.
24 Alex A, Rahmenführer J, Lengauer T. Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics 2006; 22: 1600–1607.
25 Xu LM, Li JR, Huang Y, Zhao M, Tang X, Wei L. AutismKB: an evidence-based knowledgebase of autism genetics. Nucleic Acids Res 2012; 40: D1016–D1022.
26 Basu SN, Kollu R, Banerjee-Basu S. AudDB: a gene reference resource for autism research. Nucleic Acids Res 2009; 37: D832–D836.
27 Voineagu I, Yoo HJ. Current progress and challenges in the search for autism biomarkers. Dis Markers 2013; 35: 55–65.
28 Gilman SR, Iossifov I, Levy D, Ronemus M, Wigler M, Vitek D. Rare de novo variants associated with autism implicates a large functional network of genes involved in formation and function of synapses. Neuron 2011; 70: 898–907.
29 Iossifov I, O’Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature 2014; 515: 216–221.

Neuropsychiatric risk genes during neuronal differentiation

AG Chiocchetti et al
Neuropsychiatric risk genes during neuronal differentiation
AG Chiocchetti et al

30 de Rubeis S, He X, Goldberg AP, Poutlaine CS, Samocha K, Ercument Cicak A et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 2014; 515: 209–215.

31 Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dowyer S, Gormley P et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 2014; 506: 179–184.

32 Cocchi E, Drago A, Serretti A, Hippocampal pruning as a new theory of schizo-

33 Iwata K, Matsuzaki H, Tachibana T, Ohno K, Yoshimura S, Takamura H et al. Noh HJ, Ponting CP, Boulding HC, Meader S, Betancur C, Buxbaum JD et al. Comprehensive cytogenomic pro-

34 Salimi A, Nadri S, Ghollasi M, Khajeh K, Soleimani M. Comparison of different

35 Yusuf M, Leung K, Morris KJ, Volpi EV. Comprehensive cytogenomic pro-

36 Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S et al. Transcriptional analysis of autistic brain reveals convergent molecular pathology. Nature 2011; 474: 380–384.

37 Konopka G, Wexler E, Rosen E, Mukamel Z, Osborn GE, Chen L et al. Analysis of four neuroligin genes as candidates for autism. Mol Psychiatry 2014; 15: 2392–2412.

38 McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JPA et al. Genetic architecture in autism spectrum disorder. Mol Psychiatry 2012; 17: 297–304.

39 Phillips M, Pozzo-Miller L. Dendritic spine dysgenesis in autism related disorders. Neurosci Lett 2015; 591: 30–40.

40 N-OI: 200–201.

41 Hong SE, Shugart YY, Huang DT, Shahwan SA, Grant PE, Hourihan JO et al. Autosomal recessive lissencephaly with cerebellar hypoplasia is associated with human RELN mutations. Nat Genet 2000; 26: 93–96.

42 Zaki M, Shehab M, El-Aleem AA, Abdel-Salam G, Koeller HB, Ilinik Y et al. Identification of a novel recessive RELN mutation using a homozygous balanced reci-

43 Konopka G, Wexler E, Rosen E, Mukamel Z, Osborn GE, Chen L et al. Analysis of four neuroligin genes as candidates for autism. Mol Psychiatry 2014; 15: 2392–2412.

44 Bowton E, Saunders C, Reddy IA, Campbell NG, Hamilton PJ, Henry LK et al. Neuropathology of autism: insights from a new large-scale study. Neurobiol Dis 2013; 51: 144–151.

45 Ylisauko-Oja T, Rehnstrom K, Auranen M, Vanhala R, Alen R, Kempas E et al. Analysis of four neuroligin genes as candidates for autism. Eur J Hum Genet 2005; 13: 1285–1292.

46 Rahi M, Amin M, Farzin D, Durr A, Harper J, Brice A et al. Functional analysis of neuroligin genes in autism spectrum disorders. Mol Autism 2011; 2: 338–346.

47 Zhang C, Milunsky JM, Newton S, Ko J, Zhao G, Maher TA et al. A neuroligin-4 missense mutation associated with autism impairs neuroligin-4 folding and endoplasmic reticulum export. J Neurosci 2009; 29: 10843–10854.

48 Bakos J, Babcova Z, Grant SG, Castejon AM, Ostatnikova D. Are molecules involved in neurogenesis and axon guidance related to autism pathogenesis? Neuronol Med 2015; 17: 297–304.

49 Bakos J, Babcova Z, Grant SG, Castejon AM, Ostatnikova D. Are molecules involved in neurogenesis and axon guidance related to autism pathogenesis? Neuronol Med 2015; 17: 297–304.

50 Phillips M, Pozzo-Miller L. Dendritic spine dysgenesis in autism related disorders. Neurosci Lett 2015; 601: 30–40.

51 Wang Z, Hong Y, Zou L, Zhong R, Zhu B, Shen N et al. Reelin gene variants and risk of autism spectrum disorders: an integrated meta-analysis. Am J Genet 2014; 165B: 192–200.

52 Hong SE, Shugart YY, Huang DT, Shahwan SA, Grant PE, Hourihan JO et al. Autosomal recessive lissencephaly with cerebellar hypoplasia is associated with human RELN mutations. Nat Genet 2000; 26: 93–96.

53 Zaki M, Shehab M, El-Aleem AA, Abdel-Salam G, Koeller HB, Ilinik Y et al. Identification of a novel recessive RELN mutation using a homozygous balanced reci-

54 Chiocchetti AG, Bour HS, Freitag CM. Glutamatergic candidate genes in autism spectrum disorder: an overview. J Neural Transm 2014; 121: 1081–1106.

55 McCarthy SG, Gillis J, Kramer M, Lihm J, Yoon S, Berstein Y et al. De novo mutations in schizophrenia implicate chromatin remodeling and support a genetic overlap with autism and intellectual disability. Mol Psychiatry 2014; 19: 652–658.

56 Barabasi A, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011; 12: 56–68.

57 Chiocchetti AG, Haslinger D, Boesch M, Karl T, Wiemann S, Freitag CM et al. Protein signatures of oxidative stress response in a patient-specific cell line model for autism. Mol Autism 2014; 5: 10.

58 Ben-David E, Shifman S, Gibson G. Networks of neuronal genes affected by common and rare variants in autism spectrum disorders. PLoS Genet 2012; 8: e1002556.

59 Huguet G, Ey E, Bourgeron T. The genetic landscapes of autism spectrum dis-

60 Devlin B, Scherer SW. Genetic architecture in autism spectrum disorder. Curr Opin Genet Dev 2012; 22: 229–237.

61 McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JPA et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008; 9: 356–369.

62 Gaugler T, Klei L, Sanders SJ, Bodea CA, Goldberg AP, Lee AB et al. Most genetic risk for autism resides with common variation. Nat Genet 2014; 46: 881–885.

63 Mariani J, Coppola G, Zhang P, Abyzov A, Provini L, Tommasi L et al. FOXG1-dependent dysregulation of GABA/glutamate neuron differentiation in autism spectrum disorders. Cell 2015; 162: 375–390.

64 Payca AM, Sloan SA, Clarke LE, Tian Y, Makinson CD, Huber N et al. Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture. Nat Method 2015; 12: 671–678.